Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS)

Autor: vanGilst, WH, Kingma, JH, Peels, KH, Dambrink, Jan Hendrik Everwijn
Přispěvatelé: Cardiovascular Centre (CVC)
Jazyk: angličtina
Rok vydání: 1996
Předmět:
Zdroj: Journal of the American College of Cardiology, 28(1), 114-121. ELSEVIER SCIENCE INC
ISSN: 0735-1097
Popis: Objectives. In this study we sought to investigate the effect of intervention with captopril within 6 h of the onset of myocardial infarction on left ventricular volume and clinical symptoms of heart failure in relation to infarct size during a 1-year follow-up period. Background. Remodeling of the heart starts in the early phase of myocardial infarction and is associated with an adverse prognosis, Angiotensin-converting enzyme inhibition started in the subacute or late phase after myocardial infarction has been shown to improve prognosis. Methods. In the Captopril and Thrombolysis Study, 298 patients with a first anterior myocardial infarction treated with intravenous streptokinase were randomized to receive either oral captopril (25 mg three times a day) or placebo. The left ventricular volume index was assessed by tao-dimensional echocardiography within 24 h, on days 3, 10 and 90 and after 1 year. Results. A small but significant increase in left ventricular volume indexes was observed after 12 months, Using a random coefficient model, no significant treatment effect on left ventricular volumes could be detected, In contrast, when survival models were used, the occurrence of left ventricular dilation was significantly lower in captopril-treated patients (p = 0.018), In addition, the incidence of heart failure was lower in the captopril group (p
Databáze: OpenAIRE